Jaime Alberto Bricio Barrios

Dr. Jaime Alberto Bricio Barrios

Universidad de Colima, Colima, Mexico
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Journal of International Medical Research
Verified
Journal Article
Open access
MLMarisa López
Marisa López
MRMónica Ríos-Silva
Mónica Ríos-Silva
MHMiguel Huerta
Miguel Huerta
YCYolitzy Cárdenas
Yolitzy Cárdenas
Jaime Alberto Bricio BarriosJaime Alberto Bricio Barrios
Jaime Alberto Bricio Barrios
XTXóchitl Trujillo
Xóchitl Trujillo
To evaluate the preventive effects of Moringa oleifera on metabolic syndrome (MS) in male Wistar rats. MS was induced by feeding rats a high-fat diet and drinking water containing 10% fructose for 6 weeks. In the preventive group, M. oleifera was orally administered for 3 weeks prior to the induction of MS, while in the treatment group, M. oleifera was administered for 3 weeks after the onset of MS. The treatment groups were compared with a control group of untreated rats with induced MS. Fasting glucose, oral glucose tolerance, insulin tolerance, total cholesterol, triglycerides, abdominal circumference, and systolic and diastolic blood pressure were measured before and after MS induction and/or M. oleifera treatment. After the induction of MS, the control group had higher fasting glucose levels than the preventive group. No significant differences were observed in insulin tolerance, oral glucose tolerance, cholesterol, triglycerides, abdominal circumference, or systolic or diastolic blood pressure. Compared with untreated controls, rats in the treatment group had significantly improved glucose tolerance, triglycerides, and abdominal circumference. M. oleifera treatment attenuates MS in Wistar rats.


22 May 2025 in PLOS ONE
Verified
Journal Article
Open access
OMOliver Mendoza-Cano
Oliver Mendoza-Cano
RDRogelio Danis-Lozano
Rogelio Danis-Lozano
XTXóchitl Trujillo
Xóchitl Trujillo
MHMiguel Huerta
Miguel Huerta
MRMónica Ríos-Silva
Mónica Ríos-Silva
Efrén Murillo-ZamoraEfrén Murillo-Zamora
Efrén Murillo-Zamora
Dengue is an increasing public health challenge, with rising cases and expanding distribution. Its complex epidemiology is influenced by climate change, urbanization, and the circulation of multiple viral serotypes. This study aimed to characterize the spatial and temporal (2022–2024) patterns of dengue incidence across 2,471 municipalities in Mexico. Weekly case counts, obtained through the normative epidemiological surveillance system for vector-borne diseases, were used to calculate incidence rates per 100,000 population. Geographic Information Systems were employed to analyze spatial patterns, while Local Moran’s I statistic and a k-nearest neighbors spatial weights matrix identified spatial clusters. A total of 622,689 dengue cases were analyzed, with incidence rates rising from 29.4 in 2022 to 279.0 per 100,000 in 2024. Dengue transmission expanded, affecting 38.0% of municipalities in 2022 and 68.6% by 2024 ( p < 0.001). Spatial clustering also increased, with positive clusters increasing from 28 municipalities in 2022–98 in both 2023 and 2024. Moran’s I values indicated a peak in spatial autocorrelation in 2023 (I = 0.57). While DENV-2 was the predominant serotype in 2022, DENV-3 became dominant in 2023 and 2024. Over time, high-incidence areas shifted from southern and central regions to the southeast and Pacific coast. These findings suggest the growing burden of dengue in Mexico, driven by rising incidence, expanding geographic distribution, and evolving spatial patterns. A coordinated public health response is needed to mitigate the impact of dengue and prevent its spread to newly affected areas.

28 July 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
OMOliver Mendoza-Cano
Oliver Mendoza-Cano
XTXóchitl Trujillo
Xóchitl Trujillo
MHMiguel Huerta
Miguel Huerta
MRMonica Rios-Silva
Monica Rios-Silva
JGJosé Guzmán-Esquivel
José Guzmán-Esquivel
Efrén Murillo-ZamoraEfrén Murillo-Zamora
Efrén Murillo-Zamora
The COVID-19 pandemic has had a devastating impact on global health, necessitating urgent and effective strategies to mitigate its consequences. Vaccination programs have been implemented worldwide to combat virus transmission and reduce the disease burden. This study aimed to investigate the relationship between COVID-19 vaccination coverage and all-cause excess mortality in 178 nations during the first two years of the pandemic. Multiple regression analysis, after adjusting for life expectancy at birth, confirmed a significant association between higher vaccination coverage and lower all-cause mortality rates (β = −106.8, 95% CI −175.4 to −38.2, p = 0.002). These findings underscore the importance of vaccination campaigns in reducing overall mortality during the COVID-19 pandemic. Evidence-based decision making and resource allocation can benefit from this information, facilitating the optimization of vaccination strategies for maximal impact on mortality reduction. Further research and continuous monitoring are crucial to understanding the long-term effects of vaccination coverage on population health in the ongoing pandemic.

25 June 2023 in BioMetals
Verified
Journal Article
Closed access
PDF file
MRMonica Rios-Silva
Monica Rios-Silva
YCYOLITZY CARDENAS
YOLITZY CARDENAS
AOAlan Gabriel Ortega-Macías
Alan Gabriel Ortega-Macías
XTXóchitl Trujillo
Xóchitl Trujillo
Efrén Murillo-ZamoraEfrén Murillo-Zamora
Efrén Murillo-Zamora
MHMiguel Huerta
Miguel Huerta

1 October 2016 in Journal of Nutrition in Gerontology and Geriatrics
Verified
Journal Article
Closed access
Jaime Alberto Bricio BarriosJaime Alberto Bricio Barrios
Jaime Alberto Bricio Barrios
Alin Jael Palacios FonsecaAlin Jael Palacios Fonseca
Alin Jael Palacios Fonseca
MTMario del Toro-Equihua
Mario del Toro-Equihua
CSCarmen A. Sánchez-Ramirez
Carmen A. Sánchez-Ramirez
Recent studies suggest that vitamin D plays an important role in the control of blood pressure. Unfortunately, because older adults are more likely to have low 25-hydroxyvitamin-D [25(OH)D] levels, this study investigated whether calcitriol supplementation reduces blood pressure in older adults with hypertension. The design was a double-blind placebo-controlled randomized clinical trial with 36 randomly assigned subjects (71.7 ± 10 years). Blood pressure and serum levels of 25(OH)D before and after calcitriol intervention (1,000 IU daily for 6 weeks; n = 22) or placebo (n = 23) for 6 weeks were analyzed. At the end of the study, the calcitriol group presented a significant decrease of systolic blood pressure [20.25 mmHg (p = 0.001)] and diastolic blood pressure [7 mmHg (p = 0.01)], compared with the placebo group. In conclusion, 1,000 IU/day of calcitriol for 6 weeks efficiently reduced systolic and diastolic blood pressure levels in this population of older adults presenting with high blood pressure (Clinical Trial Approbation NCT02047799).